FDA Grants Priority Review for Genzyme's Cerdelga for Gaucher Disease

Genzyme, a Sanofi company (NYSE: SNY ), announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application